Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr;11(2):145-7.
doi: 10.1159/000443494. Epub 2016 Feb 8.

Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report

Guangfu Hu  1 , Dipendra K Mallik  1 , Weige Yang  1 , Yingyong Hou  2 , Zhixiang Cheng  3 , Pu Chen  3 , Wei Zhu  1 , Hong Wang  1 , Lei Shen  1 , Hongwei Zhang  1 , Ziang Yang  1
Affiliations

Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report

Guangfu Hu et al. Breast Care (Basel). 2016 Apr.

Abstract

Background: The coexistence of breast cancer (BC) and acute myeloid leukemia (AML) has rarely been reported. Considering the fatality of AML, the management of this condition is based on treating the AML immediately while putting BC treatment on hold.

Case report: Here, we report a synchronous occurrence of BC and AML. Prognostic factors for both BC and AML were determined by genomic and molecular evaluation. The evaluation for AML showed a relatively good prognosis, and we simultaneously conducted treatment for AML and BC. The patient has survived for more than 3 years, which makes this the case with the longest survival reported.

Conclusion: In patients with BC and AML, it is essential to determine the prognosis through a genomic and molecular evaluation. For a certain group of patients whose prognosis of AML is good, simultaneous or initial treatment of BC before treatment of AML may be appropriate.

Keywords: Acute myeloid leukemia; Breast cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hematoxylin-eosin staining showing grade III invasive ductal carcinoma (×100).
Fig. 2
Fig. 2
Cellular bone marrow G/E = 2.64, with 76% blasts (×100).
Fig. 3
Fig. 3
Molecular and cytogenetic analysis showing an abnormal karyotype: 47, XX, +11(100%).
Fig. 4
Fig. 4
The patient underwent modified radical mastectomy (MRM) and an autograft of the inguinal region. A Breast cancer (BC) progression after chemotherapy for acute myeloid leukemia; B Post 3rd chemotherapy session for BC; C Post 5th chemotherapy session for BC; D 3rd week post surgery.
See this image and copyright information in PMC

References

    1. Mishra PP, Mahapatra M, Choudhry VP, et al. Synchronous occurrence of breast carcinoma and acute myeloid leukemia: case report and review of the literature. Ann Hematol. 2004;83:541–543. - PubMed
    1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115:453–474. - PubMed
    1. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26:1291–1299. - PMC - PubMed
    1. Bally C, Ades L, Renneville A, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014;38:751–755. - PubMed
    1. Linggi B, Müller-Tidow C, van de Locht L, et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia. Nat Med. 2002;8:743–750. - PubMed

LinkOut - more resources